Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
HCW Presentation September 13, 2021
Canaccord Presentation August 12, 2021
Wedbush Presentation August 11, 2021
HCW Presentation March 9, 2021
SVB Leerink Presentation Feb 24, 2021
JPM Presentation Jan 14, 2021
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Press Releases
Annual General Meeting 2023
press release
June 8, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a…
Read moreObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
press release
May 2, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 –…
Read moreObsEva Annual Report 2022
press release
April 28, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2023
June 29, 2023
ObsEva Annual General Meeting 2022
May 18, 2022
Upcoming Events
Stock Information
Latest Press Release
ObsEva Files half Year 2023 Financial Statements
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 –…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
